Unceremoniously dumped by its partner Johnson & Johnson in early 1998, Amylin struggled to carry on developing amylin--a hormone once hyped as "the missing link" in diabetes treatment. After twice failing to produce clinical evidence that the peptide benefitted diabetic patients, Amylin laid off 80% of its employees, and fell off Nasdaq's big board. Most investors dismissed the company, and their stake in it, as a lost cause. Amylin got a second chance in March 1999, via a private Series A financing. It's too soon to say whether the leap of faith by Amylin's new investors will be rewarded. The firm's aspirations for its lead drug are more modest now than in earlier days. It has no partner, and knows uncertainty still exists in the FDA process. Meanwhile, competitors' oral drugs are helping many Type 2 diabetics.
by Deborah Erickson Unceremoniously dumped by its partner
Johnson & Johnson in early 1998, Amylin struggled to carry on
developing amylin—a hormone once hyped as "the missing
link" in diabetes treatment.
Amylin Pharmaceuticals Inc. was on top of the world in June 1995. Or at least, the company's founder and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
